CTOs on the Move

Pennsylvania Environmental

www.pecpa.org

 
Pennsylvania Environmental is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pecpa.org
  • 123 Chestnut St Ste 401
    Philadelphia, PA USA 19106
  • Phone: 215.592.7020

Executives

Name Title Contact Details

Similar Companies

Complexa Inc

Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications.

Thomson Research Associates

Thomson Research Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiaKine Therapeutics

DiaKine Therapeutics is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lifeprint

Lifeprint is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.